Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial
Edward Uchio, James Steven Wysock, Arvin K. George, Thomas J. Polascik et al.
Citations
5 citations
Journal
European Urology
Topics
Microbial Inactivation Methods
Field-Weighted Citation Impact (FWCI)
6.16
article
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial
Edward Uchio, James Steven Wysock, Arvin K. George, Thomas J. Polascik, Ranko Miocinovic, David YT Chen, Amit R. Patel, Andres Correa, Ardeshir R. Rastinehad, Srinivas Vourganti, Kristian Donald Stensland, Wayne Brisbane, Derek J. Lomas, Xiaosong Meng, Jonathan Coleman, Jeffrey Gahan, Al B. Barqawi, Alice Yu, Jonathan Fainberg, Michael J. Schwartz, Abhinav Sidana, Brian T. Helfand, Timothy McClure
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
European UrologyVol. 89(1)
Institutions
Rush University Medical Center (US), Fox Chase Cancer Center (US), Northwell Health (US), Memorial Sloan Kettering Cancer Center (US), University of California, Irvine (US), Cornell University (US), Moffitt Cancer Center (US), University of Florida (US), VA Ann Arbor Healthcare System (US), Mayo Clinic in Arizona (US), The University of Texas Southwestern Medical Center (US)